Castle Biosciences to present new data from DecisionDx-Melanoma test at AAD

Castle Biosciences (CSTL) will present new data at the 2026 American Academy of Dermatology Annual Meeting, taking place March 27-31 in Denver, demonstrating that its DecisionDx-Melanoma test refines mortality risk within AJCC stages for patients with cutaneous melanoma. The data show that DecisionDx-Melanoma identifies clinically meaningful differences in mortality risk among patients within the same stage, which may help clinicians more confidently escalate care for higher-risk patients while avoiding unnecessary interventions in those at lower risk of poor outcomes.